SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN ISSUER
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
Date of Report: October 1, 1999
BIORA AB
SE-205 12 Malmo, Sweden
Telephone: (011) 46-40-32-13-33
Indicate by a check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F.
|X| Form 20-F |_| Form 40-F
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
|_| Yes |X| No
If "Yes" is marked, indicate below the file number assigned to
the registrant in connection with Rule 12g3-2(b):
Not applicable.
This Form 6-K consists of a press release issued by Biora AB on
October 1, 1999 relating to the recognition of Biora's principal product,
Emdogain, at a conference of the American Academy of Periodontology, which
ended on September 29, 1999.
October 1, 1999
President and CEO Investor Relations U.S. InvestorRelations
Tomas Hammargren Mikael Sjoblom Elisabeth Lavers
+46 40 32 13 36 + 46 40 32 13 65 +1 203 977 7797
homepage: www.biora.se
BIORA'S PRINCIPAL PRODUCT EMDOGAIN GAINED RECOGNITION
AT SPECIALIST-CONFERENCE IN THE UNITED STATES
MALMO, OCTOBER 1, 1999. BIORA AB (Nasdaq: BIORY, SSE: BIOR) today announced
that at this year's AAP conference (American Academy of Periodontology, the
leading organization for periodontology), which ended on September 29,
several American and European specialists presented their own positive
clinical experiences and supporting data concerning Emdogain, Biora's
principal product, relating to the surgical application of the product. The
conference was arranged by AAP, in San Antonio, Texas, and was attended by
approximately 6,000 periodontists and dentists from all over the world.
Among the speakers was Dr. David Cochran, Professor and Chair, Department
of Periodontics, University of Texas, Health Science Center, San Antonio
Texas, who described his new research on Emdogain's mechanism of action.
The study provides a better understanding of extracellular matrix
(Emdogain) interaction on a cellular level, further strengthening earlier
research findings that Biora presented at the International Association for
Dental Research in Vancouver, March, 1999. Another interesting study was
presented by Dr. Stuart Froum, Clinical Professor of Periodontics, Clinical
Professor of Implant Dentistry and Director of Research, Department of
Implant Dentistry, New York University. The positive results of this study
showed how Emdogain, relating to the surgical application of the product,
regenerated supporting tissues, including new bone, over a twelve-month
period.
"This is now the third time we have participated in the annual meeting for
periodontists in the United States, and each year Biora and our principal
product, Emdogain, has attracted more attention," said Tomas Hammargren,
Biora's CEO. "We believe that there is a growing acceptance of Emdogain in
the United States, based on the fact that more than half a dozen
periodontal opinion-leaders presented positive results from their clinical
experiences with the product."
Biora develops, manufactures and sells products for the treatment of
periodontal disease and for use in oral surgery. Using its proprietary
technology and expertise, Biora aims to become a world leader in
biology-based products for specialized dental therapy. Biora's American
Depository Shares are listed on the Nasdaq National Market in the US and
Biora's ordinary shares are listed on the "O-list" of the Stockholm Stock
Exchange in Sweden.
This press release may contain certain forward- looking statements that
relate to future events or future business and financial performance. Such
statements can only be predictions and the actual events or results may
differ from those discussed. The Company cautions that these statements are
subject to important factors that could cause actual results to differ
materially from those expressed or implied in such forward looking
statements and are more fully discussed in periodic reports filed with
Securities and Exchange Commission.
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
BIORA AB
Dated: October 1, 1999 By: /s/ Anders Agering
---------------------------------
Anders Agering
Chief Financial Officer
